Anticoagulant test

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Merck & Co., Inc. patent solves the following problem:

Drug-induced thrombocytopenia contribute to disease and, sometimes, the mortality in patients treated with a wide range of medicines (Karpatkin, (1971) Am. J. Med. Sci. 262, p. 68). Over 100 different drugs involved in drug-induced thrombocytopenia, including heparin, quinine, quinidine and sulfonamide antibiotics (Shulman et al. Hemostasis and thrombosis (ed 2) Philadelphia, Pa., Lippincott (1987) p .452, and Kracke et al. (1943) JAMA 122, p. 168.

Our analysis of this patent is as follows:

Merck & Co., Inc.’s patent US 6210904 B1 deals with Anticoagulant test.
The present invention is a method for diagnosing a patient at risk of thrombocytopenia induced by administration of a GP IIb / IIIa receptor antagonists, comprising combining i) a plasma sample of the patient; ii) detect monoclonal antibody they encourage cost areas formed the GP IIb / IIIa receptor association following a fibrinogen receptor antagonists of GP IIb / IIIa receptor; and iii) GP IIb / IIIa receptor: GP IIb / III receptor complex enemy, and determine associations with detectable monoclonal antibody with the complex in the presence of plasma.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.